<DOC>
	<DOCNO>NCT03004495</DOCNO>
	<brief_summary>To evaluate systemic pharmacokinetics CHF6001 follow concomitant administration CHF6001 CHF5259 , comparison single component , administer healthy subject via multi-dose reservoir NEXThaler® DPI .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Safety Inhaled CHF5259 CHF6001</brief_title>
	<detailed_description>This randomise open label , 3-way cross-over study . Each 14-day treatment period separate follow one 21-day wash-out period . Subjects reside clinic facility 14 day treatment period .</detailed_description>
	<criteria>Subject 's write informed consent obtain prior studyrelated procedure ; Healthy males female volunteer age 1855 year inclusive ; Ability understand study procedure involve risk , ability train use device correctly Non smoker exsmokers eligible . Good physical mental status , determine basis medical history general clinical examination ; Vital sign check screen visit Day 1 : Subjects age 1845years : Diastolic BP 4090 , Systolic BP 90140 ; Subjects age 4655 year : Diastolic BP 4090 , Systolic BP 90150 12lead digitise Electrocardiogram ( 12lead ECG ) consider normal ( 40≤Heart rate≤110bpm,120 m ≤ PR ≤ 210 m , QRS ≤ 120 m , QTcF ≤ 450 m male ≤ 470ms female ) check screening ; Lung function measurement within normal limit : FEV1 &gt; 80 % predict normal value ( accord Global Lung Function Initiative , ERS Task Force Lung Function Reference Values ( 1,2 ) ) FEV1/FVC ratio &gt; 0.70 ; Male subject : and/or partner childbearing potential must willing use double contraceptive method ; Female subject nonchildbearing potential ( WONCBP ) Female subject childbearing potential ( WOCBP ) fulfil one follow criterion : WOCBP fertile male partner : and/or partner childbearing potential must willing use double contraceptive method include one highly effective birth control method one acceptable birth control method , signature inform consent three month follow last study drug intake ; WOCBP nonfertile male partner : contraception require case . Pregnant lactate woman : Blood donation ( equal 450 ml ) blood loss le 12 week inhalation study medication ; Positive HIV1 HIV2 serology ; Positive result Hepatitis serology indicate acute chronic Hepatitis B Hepatitis C ( positive HB surface antigen ( HBsAg ) , HB core antibody ( anti HBc ) , HC antibody ) ; History substance abuse drug abuse within 12 month prior screen visit ; Clinically significant abnormal 24h Holter ECG screen define Holter interpretative guideline ( Appendix V ) ; Any clinically relevant abnormal laboratory value screen suggest unknown disease require clinical investigation may impact safety subject evaluation result study accord Investigator 's judgment ; Clinically significant uncontrolled respiratory , cardiac , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , respiratory psychiatric disorder may interfere successful completion protocol ; Subjects medical diagnosis asthma include childhood asthma ; Subjects know intolerance/ hypersensitivity M3 Antagonists , excipients contain formulation use trial ; Any drug treatment , include prescribed OTC medicine well vitamin , homeopathic remedy etc , take 14 day ( 3 month biologic drug , enzymeinducing enzymeinhibiting drug e.g. , glucocorticoid , phenobarbital , isoniazid ) screen visit , exception occasional paracetamol ( maximum 2 g per day maximum 10 g per 14 day mild nonexcluding condition ) , hormonal contraceptive hormonal replacement treatment postmenopausal woman ; Treatment within previous 3 month screen visit drug know well define potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>